Nektar Therapeutics | NKTR - Los Gastos Financieros De La Deuda

Precio De Mercado
77.50
Cambio Diario
-0.35 -0.45%
Mensual
5.69%
Anual
736.44%
Q2 Expectativa
75.38




Los Gastos Financieros De La Deuda Cambio Fecha
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
ALKERMES USD 12.28M 7.63M 2025-12
Amgen USD 653M 32M 2025-12
Baxter International USD 58M 14M 2025-09
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 432M 48M 2025-12
Cara Therapeutics 39.02M 4.73M 2025-09
Cipla INR 140.3M 8.5M 2025-12
Dr.Reddys Laboratories INR 944M 37M 2025-12
Eisai JPY 1.43B 12M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 4.91M 615K 2025-12
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 412M 85M 2025-12
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Takeda JPY 123.63B 40.49B 2025-12
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Xencor USD 7.35M 311K 2025-12